{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Chris+Green&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&publisher.prefLabel=House+of+Commons&_metadata=all&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&_page=0&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1139686", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139686/answer", "answerText" : {"_value" : "

New European Union Regulations for medical devices (MDR) entered into force in May 2017 and will fully apply from May 2020.<\/p>

The new Regulations substantially strengthen the regulatory framework for medical devices and notified bodies are having to make significant changes to meet the enhanced requirements. These changes have the aim of improving the quality, consistency and rigour of notified body assessments, which was one of the Government\u2019s key aims for the new legislation.<\/p>

Ministers have met with and received letters from industry representatives who have raised concerns about capacity in the notified body sector across the EU to support the implementation of the MDR. The Government recognises the importance of having competent notified bodies across the EU in place in sufficient time to ensure continuity of supply of products to the United Kingdom market.<\/p>

For this reason, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council on 14 June, the Parliamentary Under-Secretary of State (Baroness Blackwood of North Oxford) raised the Government\u2019s concerns about the readiness of critical infrastructure required to implement the MDR and the risk that some existing and new to market products will not be available to patients as a result.<\/p>

We very much recognise the benefits of the new Regulations and the imperative of full implementation as soon as possible in the interests of patient safety. Therefore, at EPSCO the Government emphasised the importance of finding a coordinated solution at an EU level and we will continue to do what we can to influence these discussions.<\/p>

In parallel with this activity, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with its notified bodies on an ongoing basis to ensure that sufficient resources are in place and notified bodies are prepared for the implementation of the new EU legislation. The MHRA is also offering a substantial amount of resource to the EU in order to support and expedite the designation process.<\/p>

Through the Office for Life Sciences, the Government plans to work with stakeholders to come to a shared understanding of the issues and discuss what further mitigating action could be taken. Further engagement with industry will therefore take place in the short term.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "277763"} , {"_value" : "277764"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-25T10:00:04.983Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Equipment: UK Notified Bodies"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the number of notified bodies to service medical devices under the terms of the Medical Devices Regulation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "278523"} , {"_about" : "http://data.parliament.uk/resources/1139219", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139219/answer", "answerText" : {"_value" : "

New European Union Regulations for medical devices (MDR) entered into force in May 2017 and will fully apply from May 2020.<\/p>

The new Regulations substantially strengthen the regulatory framework for medical devices and notified bodies are having to make significant changes to meet the enhanced requirements. These changes have the aim of improving the quality, consistency and rigour of notified body assessments, which was one of the Government\u2019s key aims for the new legislation.<\/p>

Ministers have met with and received letters from industry representatives who have raised concerns about capacity in the notified body sector across the EU to support the implementation of the MDR. The Government recognises the importance of having competent notified bodies across the EU in place in sufficient time to ensure continuity of supply of products to the United Kingdom market.<\/p>

For this reason, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council on 14 June, the Parliamentary Under-Secretary of State (Baroness Blackwood of North Oxford) raised the Government\u2019s concerns about the readiness of critical infrastructure required to implement the MDR and the risk that some existing and new to market products will not be available to patients as a result.<\/p>

We very much recognise the benefits of the new Regulations and the imperative of full implementation as soon as possible in the interests of patient safety. Therefore, at EPSCO the Government emphasised the importance of finding a coordinated solution at an EU level and we will continue to do what we can to influence these discussions.<\/p>

In parallel with this activity, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with its notified bodies on an ongoing basis to ensure that sufficient resources are in place and notified bodies are prepared for the implementation of the new EU legislation. The MHRA is also offering a substantial amount of resource to the EU in order to support and expedite the designation process.<\/p>

Through the Office for Life Sciences, the Government plans to work with stakeholders to come to a shared understanding of the issues and discuss what further mitigating action could be taken. Further engagement with industry will therefore take place in the short term.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "277764"} , {"_value" : "278523"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-25T10:00:04.89Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Equipment: UK Notified Bodies"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent representations he has received from the medical technology sector on the capacity of Notified Bodies to meet the demand for their services under the provisions of the Medical Devices Regulation; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "277763"} , {"_about" : "http://data.parliament.uk/resources/1139220", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139220/answer", "answerText" : {"_value" : "

New European Union Regulations for medical devices (MDR) entered into force in May 2017 and will fully apply from May 2020.<\/p>

The new Regulations substantially strengthen the regulatory framework for medical devices and notified bodies are having to make significant changes to meet the enhanced requirements. These changes have the aim of improving the quality, consistency and rigour of notified body assessments, which was one of the Government\u2019s key aims for the new legislation.<\/p>

Ministers have met with and received letters from industry representatives who have raised concerns about capacity in the notified body sector across the EU to support the implementation of the MDR. The Government recognises the importance of having competent notified bodies across the EU in place in sufficient time to ensure continuity of supply of products to the United Kingdom market.<\/p>

For this reason, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council on 14 June, the Parliamentary Under-Secretary of State (Baroness Blackwood of North Oxford) raised the Government\u2019s concerns about the readiness of critical infrastructure required to implement the MDR and the risk that some existing and new to market products will not be available to patients as a result.<\/p>

We very much recognise the benefits of the new Regulations and the imperative of full implementation as soon as possible in the interests of patient safety. Therefore, at EPSCO the Government emphasised the importance of finding a coordinated solution at an EU level and we will continue to do what we can to influence these discussions.<\/p>

In parallel with this activity, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with its notified bodies on an ongoing basis to ensure that sufficient resources are in place and notified bodies are prepared for the implementation of the new EU legislation. The MHRA is also offering a substantial amount of resource to the EU in order to support and expedite the designation process.<\/p>

Through the Office for Life Sciences, the Government plans to work with stakeholders to come to a shared understanding of the issues and discuss what further mitigating action could be taken. Further engagement with industry will therefore take place in the short term.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "277763"} , {"_value" : "278523"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-25T10:00:04.937Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Devices (Amendment etc.) (EU Exit) Regulations 2019"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he plans to seek an extension to the implementation period of the Medical Devices Regulation from the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "277764"} , {"_about" : "http://data.parliament.uk/resources/1139222", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139222/answer", "answerText" : {"_value" : "

I refer the hon. Member to the answer I gave the hon. Member for Newcastle upon Tyne Central (Chi Onwurah MP) on 9 May 2019 to Question 249283<\/a>. Further to that answer, on 11 July 2019 the Government announced £135 million of funding to support National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs). The NIHR ARC scheme will support high-quality applied health and care research to make tangible improvements for patients, the public and to health and care services. NIHR ARCs will work with local partners and patients and the public from across the local communities they serve, and particularly with Academic Health Science Networks, to tackle local health and care priorities.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"} } , "answeringMemberConstituency" : {"_value" : "Kingswood"} , "answeringMemberPrinted" : {"_value" : "Chris Skidmore"} , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-22T15:18:24.917Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Research: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the equity of the distribution of research and development spending for areas with poor health outcomes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "277765"} , {"_about" : "http://data.parliament.uk/resources/1139223", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139223/answer", "answerText" : {"_value" : "

The 2.4% R&D Roadmap will set overall direction for how we can achieve the 2.4% R&D ambition by 2027, and 3% in the longer term, through the use of strategic public funding to leverage private R&D investment.<\/p>

It aims to transform R&D intensity across all sectors of the economy, supporting the development of new technologies, industries, and products that bring growth, good jobs across the UK, and social improvements for all.<\/p>

The 2.4% R&D Roadmap will bring together Government, academia, and industry to collaboratively focus their efforts on increasing R&D investment. In the area of health, this includes the Department of Health and Social Care and NHS R&D activity, and work with industry in taking forward the Life Sciences Sector Deal. The 2.4% R&D Roadmap will also align closely with the Industrial Strategy\u2019s Grand Challenges. This includes the Ageing Society Grand Challenge which will create new demands for technologies, products and services for an ageing population, and the AI and Data Grand Challenge which will use data, artificial intelligence, and innovation to transform the prevention, early diagnosis, and treatment of diseases like cancer, diabetes, heart disease, and dementia by 2030.<\/p>

In order to achieve the 2.4% R&D target, we need to accelerate the growth and build on R&D strengths across the UK. The Government has put in place a number of initiatives to support every part of the UK to identify and leverage their R&D strengths, from Science and Innovation Audits to the Strength in Places Fund. The Strength in Places Fund (SIPF) is investing £237m up to 2021-22 in growing new and existing centres of excellence for research and innovation across the UK.<\/p>

We are working with Local Economic Partnerships as they develop Local Industrial Strategies to identify science and innovation strengths and the action needed to unlock R&D growth in places across the country.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"} } , "answeringMemberConstituency" : {"_value" : "Kingswood"} , "answeringMemberPrinted" : {"_value" : "Chris Skidmore"} , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-22T15:15:15.653Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Research: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he plans to take to ensure that the Government's target of increasing research and development funding to 2.4 per cent of GDP benefits the areas with the poorest health outcomes, particularly parts of the north of England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "277766"} , {"_about" : "http://data.parliament.uk/resources/1138235", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1138235/answer", "answerText" : {"_value" : "

As for all NHS England campaigns, the adequacy of the funding for the \u2018NHS Help Us Help You Winter Pressures\u2019 campaign is measured by the effectiveness of the campaign in achieving it objectives, which are set.<\/p>

The independent evaluation research showed that the 2018/19 \u2018NHS Help Us Help You Winter Pressures\u2019 campaign successfully achieved 15 of the 18 objectives set before the activity started. The \u2018NHS Help Us Help You Winter Pressures\u2019 campaign budget for 2019/20 has been reduced by 7.5% when compared to the budget for 2018/19. However, NHS England expects to deliver similar levels of effectiveness.<\/p>

<\/p>

<\/p>

<\/strong><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-07-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-16T16:08:01.02Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Weather: Health Education"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the funding allocated to the NHS Help us help you to stay well this winter campaign in the (a) last and (b) next 12 months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "275776"} , {"_about" : "http://data.parliament.uk/resources/1138237", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1138237/answer", "answerText" : {"_value" : "

Public Health England is planning to spend £1,300,000 on a flu vaccination campaign to encourage eligible members of the public and health and social care workers to take up the free vaccine ahead of the winter season. The spend includes expenditure for advertising on television, radio, national and regional press, outdoor, digital, and printing, excluding VAT. Figures provided are provisional and need to be reconciled following the campaign\u2019s conclusion in November.<\/p>

Flu marketing resources can be viewed at following link:<\/p>

https://campaignresources.phe.gov.uk/resources/campaigns/34-stay-well-this-winter-/resources<\/a><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-07-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-18T09:01:30.307Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Influenza: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how much funding his Department has committed to spend on campaigns to promote flu vaccination in 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "275777"} , {"_about" : "http://data.parliament.uk/resources/1128437", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1128437/answer", "answerText" : {"_value" : "

The National Institute for Health and Care Excellence takes into account the availability of medicines through the Early Access to Medicines Scheme (EAMS) in terms of scheduling its assessments, however the process followed in assessing the technology is the same as for non-EAMS technologies.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-07T14:54:05.017Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether (a) NICE and (b) NHS England take into account the availability of medicines under the Early Access to Medicines Scheme when assessing those same medicines for approval as new medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "257759"} , {"_about" : "http://data.parliament.uk/resources/1127772", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127772/answer", "answerText" : {"_value" : "

The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department\u2019s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.<\/p>

The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-30T10:52:06.847Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Voluntary Scheme for Branded Medicines Pricing and Access"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "257056"} , {"_about" : "http://data.parliament.uk/resources/1122385", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1122385/answer", "answerText" : {"_value" : "

Through our modern Industrial Strategy we have committed to the highest R&D increase on record. We have announced increases in public R&D spending worth £7bn up to 2021/2022, and we are working with UK Research and Innovation and other key partners to develop a roadmap that sets out how government and industry will work together to reach our target of increasing R&D investment to 2.4% of GDP by 2027, which would be the highest recorded level, and 3% in the longer-term.<\/p>

<\/p>

The Government recognises that to make best use of this increased level of investment in science we will need to increase the number of researchers and strengthen the pipeline leading to research careers. Though it is too early to assess the impacts of these new programmes we are addressing this need through such programmes as UK Research and Innovation\u2019s £900m Future Leaders Fellowship which aims to attract the best researchers from the UK and from around the world.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"} } , "answeringMemberConstituency" : {"_value" : "Kingswood"} , "answeringMemberPrinted" : {"_value" : "Chris Skidmore"} , "dateOfAnswer" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-04-29T15:24:40.883Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2019-04-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "STEM Subjects: Research"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has plans to increase Government funding to support the STEM research sector; and what recent assessment he has made of the effect of such Government funding on changes in the number of highly skilled people working in that sector.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"} } , "tablingMemberConstituency" : {"_value" : "Bolton West"} , "tablingMemberPrinted" : [{"_value" : "Chris Green"} ], "uin" : "246536"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Chris+Green&_page=1&publisher.prefLabel=House+of+Commons&max-questionFirstAnswered.=2019-09-09T15%3A00%3A41.437Z", "page" : 0, "startIndex" : 1, "totalResults" : 144, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }